Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation - The New England Journal of Medicine - 2019

Brief Summary:

Among patients with AF presenting with ACS or undergoing PCI, apixaban is associated with a 4.2% absolute reduction in major or clinically relevant nonmajor bleeding when compared to warfarin at 180 days. Apixaban was also associated with a 3.9% absolute reduction in death or hospitalization when compared to warfarin (driven primarily by reduced hospitalization). Aspirin use in addition to oral anticoagulation and P2Y12 inhibitor therapy was associated with a 7.1% absolute increase in major or clinically relevant nonmajor bleeding. Overall thrombotic events were similar across individuals randomized to anticoagulation with apixaban versus warfarin, and those randomized to aspirin versus placebo.



  1. Amazing, What an Excellent post. I truly discovered this an excessive amount of data. It is the thing that I was looking for.I might want to recommend you that please continue sharing such kind of information. buy apixaban


Post a comment